Zynex Collapse Triggers Securities Class Action After $85M Fraud Settlement

Hagens Berman, a prominent securities litigation firm, has filed a class action lawsuit against Zynex, Inc. ($ZYXI / $ZYXIQ) and its former executives, marking the latest chapter in a dramatic corporate implosion that has wiped out shareholder value and triggered federal fraud investigations. The lawsuit follows Zynex's delisting and Chapter 11 bankruptcy filing, culminating months of financial deterioration that began when the company's largest payor, Tricare, suspended payments in early 2025. The action underscores the severe consequences of alleged systematic fraud in the medical device and healthcare supply sector, where regulatory oversight and payor scrutiny have intensified sharply in recent years.

The Alleged Oversupplying Scheme and Financial Reckoning

According to the litigation, Zynex engaged in a systematic 'oversupplying' scheme in which the company shipped excessive medical supplies to patients while simultaneously overbilling government and private payors. This fraudulent business model, allegedly orchestrated at the highest levels of management, artificially inflated revenues and obscured the company's true operational health from investors—a classic securities fraud red flag.

The financial impact has been severe and immediate:

• $85 million+ in forfeitures to resolve fraud allegations with federal authorities
• Tricare suspension of all payments in early 2025, eliminating the company's primary revenue stream
• Delisting from public markets, triggering automatic removal from most institutional portfolios
• Chapter 11 bankruptcy filing, indicating the company lacked sufficient liquidity to meet its obligations

The timing of Tricare's payment suspension proved catastrophic. As the federal healthcare program for active-duty military personnel and retirees, Tricare represents one of the largest payor networks in American healthcare. Its decision to cut off payments effectively severed Zynex's financial lifeline, demonstrating the existential risk that government payors pose to medical device and supply companies dependent on federal reimbursement.

Criminal Charges and Executive Accountability

The legal reckoning extended beyond civil securities litigation into criminal territory. In January 2026, former CEO Thomas Sandgaard and former COO Anna Lucsok were indicted on healthcare and securities fraud charges. These criminal proceedings represent a significant escalation, signaling that federal prosecutors believed evidence supported charges of intentional wrongdoing rather than mere negligence or compliance failures.

The dual charging strategy—healthcare fraud alongside securities fraud—reflects the interconnected nature of the alleged misconduct. By defrauding payors through oversupplying, Zynex executives simultaneously deceived securities investors about the legitimacy of revenue recognition and the sustainability of the business model. This convergence of criminal exposure creates substantial legal jeopardy for the defendants and underscores prosecutors' confidence in their evidence.

Market Context: Healthcare Fraud Under Intense Scrutiny

Zynex's collapse arrives amid an unprecedented enforcement environment in healthcare fraud prosecution. Federal agencies, including the Department of Justice, Department of Health and Human Services Office of Inspector General, and state attorneys general, have prioritized medical device and supply fraud cases, particularly those involving government payors like Medicare, Medicaid, and Tricare.

The oversupplying scheme alleged at Zynex mirrors patterns observed in other healthcare fraud cases:

• Supplier-induced demand: Shipping unnecessary quantities to inflate utilization metrics and billing volumes
• Payor exploitation: Leveraging asymmetric information and automated billing systems to bill for supplies that patients never received or needed
• Government program targeting: Disproportionately exploiting federal payors, which operate under reimbursement formulas that can reward volume

In the competitive landscape of medical devices and supplies, companies like Inogen ($INGN), ResMed ($RMD), and Philips Healthcare operate under far tighter compliance regimens following high-profile enforcement actions across the sector. The Zynex case serves as a cautionary tale about the fragility of growth-at-all-costs strategies in heavily regulated healthcare markets.

Investor Implications: Shareholder Losses and Litigation Recoveries

For shareholders who purchased Zynex stock at prices reflecting the alleged fraud, the class action lawsuit represents one of few remaining avenues for financial recovery. However, recoveries in bankrupt companies are typically modest, as courts prioritize secured creditors and employees ahead of equity holders.

Key considerations for investors:

• Timing of share purchases: Class action plaintiffs must have purchased shares during the alleged fraud period—typically the entire period before public disclosures corrected the misleading statements
• Bankruptcy priority: In Chapter 11 proceedings, common equity holders rank last among claimants, often receiving pennies on the dollar or nothing at all
• Settlement dynamics: Many securities class actions settle for 5-10% of claimed damages, depending on available insurance and executive indemnification agreements
• Regulatory lessons: The case reinforces the importance of supply chain transparency, payor concentration risk, and independent auditor scrutiny in healthcare-dependent businesses

Broader market implications extend beyond Zynex itself. The case highlights ongoing risk factors in the healthcare supply sector: payor concentration, regulatory exposure, and the persistent temptation to manipulate volumes rather than develop genuine value-added solutions. Investors in comparable companies should examine:

• Payor concentration metrics: What percentage of revenue depends on any single payor, especially government programs?
• Compliance infrastructure: How robust are internal controls, audit functions, and regulatory reporting systems?
• Revenue quality: Are growth rates supported by genuine demand or supply-side manipulation?

Looking Forward

The Zynex ($ZYXI / $ZYXIQ) collapse—from alleged systematic fraud through delisting, bankruptcy, and criminal indictments—exemplifies the catastrophic consequences of prioritizing short-term revenue growth over genuine operational integrity in regulated healthcare markets. The securities class action filed by Hagens Berman offers affected shareholders a path toward potential recovery, though realistic assessments suggest limited outcomes given the company's bankruptcy status.

For the broader healthcare investment community, the case serves as both a compliance lesson and a risk indicator. Regulators have demonstrated their capacity and willingness to prosecute complex healthcare fraud aggressively, while payors have shown they will abruptly terminate relationships with offending suppliers. Investors should apply heightened scrutiny to healthcare suppliers exhibiting revenue concentration, limited compliance transparency, or aggressive growth trajectories unexplained by market fundamentals. In regulated industries, integrity is not merely ethical—it is existential.